Alessandra Cesano
CIK 1827015 · Chief Medical Officer · last filed 2026-01-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$306.8K
Companies
4
Total Filings
17
Lifetime Open-Market Net
-$132.2K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZYME | Director | — | $22.88 | — | $0 | 3 | 2026-01-12 |
| SMMT | Director | — | $14.01 | — | $0 | 5 | 2026-01-06 |
| PBYI | Director | 41,850 | $7.33 | $306.8K | -$132.2K | 6 | 2025-07-22 |
| ESSA Pharma Inc. (EPIX) Delisted | Chief Medical Officer | — | $0.20 | — | $0 | 3 | 2024-03-28 |
Recent Filings · Page 2 of 2
17 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-01-04 | SMMT | Grant (A) | — | $0 | EDGAR |
| 2023-06-15 | PBYI | Grant (A) | +27,000 | $0 | EDGAR |
| 2023-01-05 | SMMT | Grant (A) | — | $0 | EDGAR |
| 2022-11-17 | SMMT | Grant (A) | — | $0 | EDGAR |
| 2022-11-01 | ESSA Pharma Inc. (EPIX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-08-02 | PBYI | Grant (A) | — | $0 | EDGAR |
| 2021-01-11 | ESSA Pharma Inc. (EPIX) Delisted | Grant (A) | — | $0 | EDGAR |
Showing 11–17 of 17
Prev
Page 2 of 2
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.